Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 242
Tipo Título / Nombre Autor(es) Año
Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies? Sánchez-Correa B, Campos C, Pera A, Bergua JM, Arcos MJ, Bañas H, Casado JG, Morgado S, Duran E, Solana R, Tarazona R 2016
High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test Montesinos P, Ballesteros J, Martinez Cuadrón D, Martínez López J, Serrano J, Pérez de Oteyza J, Fernández P, Rodríguez Macías G, Vidriales MB, Herrera P, Tormo M, Bergua J, García R, Vives S, Fernández MA, Lavilla E, Jiménez S, Péres Simón JA, Simiele A, González A, González BJ, Burgaleta C [et.al] 2015
Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry Gironella M, Bergua J, Fernández de Larrea C, Escalante F, González M, Martínez Chamorro C, López A, Pérez Persona E, Lahuerta JJ, Somilinos N, Soler A, González Y, Suárez Cabrera A, Barez A, Cabañas V, Sampol A, González AP, Giselle Lostaunau , Vilanova D, Alegre A 2015
Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). P Ribera JM, Morgades M, Ciudad J, Barba P, Martino R, Montesinos P, Vives S, Moreno MJ, Soria B, Cil C, González Campos J, Amigo ML, Novo A, Torno M, Bermudéz A, Serrano A, Bernal T, López A, Bergua J, Escoda L, Martínez P, Alonso N, Mercadas S, Abella E, Cuardia R, Vall-llovera F, Cladera A, Esteve J, García Boyero R, Feliu E, Orfao A 2015
Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain Pineda A, Sancho JM, García O, Esteve J, Tormo M, Martínez P, Vall-llovera F, Martino R, Montesinos P, González Campos J, Bergua J, Calbacho M, Gil C, Vicent A, Cladera A, Hernández J, Moreno MJ, Serrano A, Alonso N, García R, Barba P, Fernández A, Miralles P, Novo A, Moraleda JM, Hernández JA, Abella E, Sánchez M, López ME, Bernal T, Mateos MC, Lavilla E, Ribera JM 2015
Relationship between Antiphospholipid Syndrome clinical manifestations and multiple positive antiphospholipid antibodies. Sigüenza R, Bermejo N, Casas I, Ibañez F, Bañas MH, Bergua JM, Arcos MJ, Prieto J, Martin-Mateos ML, Cabrera C, Perez-Leal FA 2015
CD38 expression on CD34+ Bone Marrow Cells (BM) as a tool in low grade Myelodysplactics Syndromes (MDS) Sigüenza R, Bañas MH, Casas I, Ibañez F, Bermejo N, Bergua JM, Arcos MJ, Prieto J, Martin-Mateos ML, Cabrera C, Perez-Leal FA 2015
Long-term anticoagulation with dabigatran in patients with severe lactose intolerance Bermejo N, Sigúenza R, Ibañez F, Bañas MH, Casas I, Pérez-Leal FA, Bergua J 2015
Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score Falantes JF, Martinez Robles V, Bargay J, Deben G, Garrido A, Casano J, Salamero O, Bergua JM, Colado E, Garcia R, Pedro C, Redondo S, Tormo M, Bonanad S, Diez-Campelo M, Perez-Encinas M, de la Fuente A, Xicoy B, Montesinos P, 2015
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group Purroy N, Bergua J, Gallur L, Prieto J, López LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, López A 2015